메뉴 건너뛰기




Volumn 38, Issue 9, 2008, Pages 933-936

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial)

Author keywords

"wearingoff"phenomenon; COMT; Constant dopaminergic stimulation; Entacapone; Fluctuation; Parkinson's disease; Stalevo

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; ENTACAPONE; LEVODOPA;

EID: 56249139362     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-008-9085-3     Document Type: Article
Times cited : (10)

References (22)
  • 1
    • 2142781633 scopus 로고    scopus 로고
    • "Experience in the use of dopamine receptor agonists in the out-patient treatment of Parkinson's disease"
    • A. N. Boiko, T. T. Batysheva, E. S. Chikina, et al., "Experience in the use of dopamine receptor agonists in the out-patient treatment of Parkinson's disease," Zh. Nevrol. Psikhiat., 103, No. 9, 54-58 (2003).
    • (2003) Zh. Nevrol. Psikhiat. , vol.103 , Issue.9 , pp. 54-58
    • Boiko, A.N.1    Batysheva, T.T.2    Chikina, E.S.3
  • 2
    • 18244384502 scopus 로고    scopus 로고
    • "Use of Tremonorm in Parkinson's disease: Experience of the out-patient neurological service of the Moscow City Health System"
    • A. N. Boiko, T. T. Batysheva, E. S. Chikina, et al., "Use of Tremonorm in Parkinson's disease: Experience of the out-patient neurological service of the Moscow City Health System," Zh. Nevrol. Psikhiat., 104, No. 12, 23-28 (2004).
    • (2004) Zh. Nevrol. Psikhiat. , vol.104 , Issue.12 , pp. 23-28
    • Boiko, A.N.1    Batysheva, T.T.2    Chikina, E.S.3
  • 3
    • 56249092912 scopus 로고    scopus 로고
    • "Efficacy of PK-Merz in Parkinson's disease in out-patient practice"
    • A. N. Boiko, T. T. Batysheva, E. S. Chikina, et al., "Efficacy of PK-Merz in Parkinson's disease in out-patient practice," Lech. Nerv. Bolezn., 2, 23-27 (2005).
    • (2005) Lech. Nerv. Bolezn. , vol.2 , pp. 23-27
    • Boiko, A.N.1    Batysheva, T.T.2    Chikina, E.S.3
  • 5
    • 56249107826 scopus 로고    scopus 로고
    • "New possibilities in the treatment of Parkinson's disease with Stalevo (levodopa/carbidopa/entacapone)"
    • V. L. Golubev and A. A. Palipovich, "New possibilities in the treatment of Parkinson's disease with Stalevo (levodopa/carbidopa/ entacapone)," Lech. Nerv. Bolezn., 1, 1-11 (2006).
    • (2006) Lech. Nerv. Bolezn. , vol.1 , pp. 1-11
    • Golubev, V.L.1    Palipovich, A.A.2
  • 6
    • 56249110726 scopus 로고    scopus 로고
    • "Development of motor fluctuations in patients with different stages of Parkinson's disease"
    • O. S. Levin, "Development of motor fluctuations in patients with different stages of Parkinson's disease," Atmosfera (Nerv. Bolezn., 1, 10-16 (2005).
    • (2005) Atmosfera Nerv. Bolezn. , vol.1 , pp. 10-16
    • Levin, O.S.1
  • 8
    • 56249136063 scopus 로고    scopus 로고
    • "Use of catechol-O-methyltransferase (COMT) inhibitors in the treatment of the late stages of Parkinson's disease"
    • N. V. Fedorova, O. V. Krivonos, I. P. Chigir', et al., "Use of catechol-O-methyltransferase (COMT) inhibitors in the treatment of the late stages of Parkinson's disease," Kreml. Med., 2, 66-72 (2001).
    • (2001) Kreml. Med. , vol.2 , pp. 66-72
    • Fedorova, N.V.1    Krivonos, O.V.2    Chigir', I.P.3
  • 9
    • 69149103832 scopus 로고    scopus 로고
    • "A new-generation levodopa preparation "Stalevo (levodopa/ carbidopa/entacapone), in the treatment of Parkinson's disease"
    • N. V. Fedorova, O. S. Levin, I. G. Smolentseva, et al., "A new-generation levodopa preparation " Stalevo (levodopa/carbidopa/ entacapone), in the treatment of Parkinson's disease," Zh. Nevrol. Psikhiat., 9, 39-46 (2006).
    • (2006) Zh. Nevrol. Psikhiat. , vol.9 , pp. 39-46
    • Fedorova, N.V.1    Levin, O.S.2    Smolentseva, I.G.3
  • 11
    • 0041704637 scopus 로고    scopus 로고
    • "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study"
    • the UK-Irish Entacapone study group
    • D. Brooks, H. Sagar, and the UK-Irish Entacapone study group, "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study," J. Neurol. Neurosurg. Psychiat., 74, 1064-1072 (2003).
    • (2003) J. Neurol. Neurosurg. Psychiat. , vol.74 , pp. 1064-1072
    • Brooks, D.1    Sagar, H.2
  • 12
    • 22744453722 scopus 로고    scopus 로고
    • "NC-INIT Study Group. Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment"
    • D. Brooks, Y. Agid, K. Eggert, et al., "NC-INIT Study Group. Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment," Eur. Neurol., 53, No. 4, 197-202 (2005).
    • (2005) Eur. Neurol. , vol.53 , Issue.4 , pp. 197-202
    • Brooks, D.1    Agid, Y.2    Eggert, K.3
  • 13
    • 0347092046 scopus 로고    scopus 로고
    • "Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation"
    • P. Jenner, "Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation," Neurology, 62, Supplement 1, 47-55 (2004).
    • (2004) Neurology , vol.62 , Issue.SUPPL. 1 , pp. 47-55
    • Jenner, P.1
  • 14
    • 33645540098 scopus 로고    scopus 로고
    • "Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels"
    • T. Müller, C. Erdmann, S. Muhlack, et al., "Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels," Mov. Dis., 21, No. 3, 332-336 (2006).
    • (2006) Mov. Dis. , vol.21 , Issue.3 , pp. 332-336
    • Müller, T.1    Erdmann, C.2    Muhlack, S.3
  • 15
    • 12544252127 scopus 로고    scopus 로고
    • "Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease"
    • D. Nyholm, A. I. Nilsson Remahl, N. Disdar, et al., "Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease," Neurology, 64, No. 2, 216-223 (2005).
    • (2005) Neurology , vol.64 , Issue.2 , pp. 216-223
    • Nyholm, D.1    Nilsson Remahl, A.I.2    Disdar, N.3
  • 16
    • 5344247928 scopus 로고    scopus 로고
    • "Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease"
    • C. W. Olanow, K. Kieburtz, M. Stern, et al., "Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease," Arch. Neurol., 61, No. 10, 1563-1568 (2004).
    • (2004) Arch. Neurol. , vol.61 , Issue.10 , pp. 1563-1568
    • Olanow, C.W.1    Kieburtz, K.2    Stern, M.3
  • 17
    • 0347092036 scopus 로고    scopus 로고
    • "COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?"
    • C. W. Olanow and F. Stocchi, "COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?" Neurology, 62, Supplement 1, 72-81 (2004).
    • (2004) Neurology , vol.62 , Issue.SUPPL. 1 , pp. 72-81
    • Olanow, C.W.1    Stocchi, F.2
  • 18
    • 0030882893 scopus 로고    scopus 로고
    • "Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: Pharmacokinetic and quality-of-life measures"
    • R. Pahwa, K. Lyons, D. McGuire, et al., "Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: Pharmacokinetic and quality-of-life measures," Mov. Dis., 12, No. 5, 677-681 (1997).
    • (1997) Mov. Dis. , vol.12 , Issue.5 , pp. 677-681
    • Pahwa, R.1    Lyons, K.2    McGuire, D.3
  • 19
    • 0346576032 scopus 로고    scopus 로고
    • "Levodopa in Parkinson's Disease: Mechanisms of action and pathophysiology of late failure"
    • in: J. J. Jankovic and E. Tolosa (eds.)
    • W. Poewe and G. Wenning, "Levodopa in Parkinson's Disease: mechanisms of action and pathophysiology of late failure," in: Parkinson's Disease, Movement Disorders, J. J. Jankovic and E. Tolosa (eds.) (2002), pp. 104-115.
    • (2002) Parkinson's Disease, Movement Disorders , pp. 104-115
    • Poewe, W.1    Wenning, G.2
  • 20
    • 0036113588 scopus 로고    scopus 로고
    • "Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)"
    • W. H. Poewe, G. Deuschl, A. Gardin, et al., "Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)," Acta Neurol. Scand., 105, 245-255 (2002).
    • (2002) Acta Neurol. Scand. , vol.105 , pp. 245-255
    • Poewe, W.H.1    Deuschl, G.2    Gardin, A.3
  • 21
    • 33644824423 scopus 로고    scopus 로고
    • "Timing of treatment initiation in Parkinson's disease: A need for reappraisal"
    • A. H. Schapiro and J. Obeso, "Timing of treatment initiation in Parkinson's disease: A need for reappraisal," Ann. Neurol., 59, No. 3, 559-562 (2006).
    • (2006) Ann. Neurol. , vol.59 , Issue.3 , pp. 559-562
    • Schapiro, A.H.1    Obeso, J.2
  • 22
    • 19344378940 scopus 로고    scopus 로고
    • "Entacapone in the treatment of Parkinson's disease"
    • A. Schrag, "Entacapone in the treatment of Parkinson's disease," Lancet. Neurol., 4, No. 6, 366-370 (2005).
    • (2005) Lancet. Neurol. , vol.4 , Issue.6 , pp. 366-370
    • Schrag, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.